Dr. Pestell founded ProstaGene to rapidly bring to cancer patients the benefits of the prostate cancer testing and metastasis technologies discovered under his leadership at the Sidney Kimmel Cancer Center. He is the inventor of record in the ProstaGene patents. He is leading ProstaGene as an active Board Chair, is directly engaged in the recruitment of a fulltime CEO and a Senior Licensing Executive, and will continue to provide Board Chair leadership in the future.
ProstaGene was assigned new patents in prostate cancer.
Issued Patent No. 2012225232, Title: “Prostate Cancer Cell Lines, Gene Signatures And Uses Thereof“. Ref. 140993.00105 AU. issued August 25, 2016
ProstaGene was assigned important patents for cancer treatment.
US Patent issued September 27, 2016 as U.S. Patent No. 9,453,836. Use of modulators of CCR5 in the treatment of cancer and cancer metastasis” US Provisional Patent Application Nos. 61/646,593 and 61/646,586 (Reference Nos. 010236-5002-PR & 010236-5002-PR1)
The new Prostagene website is now live. Check back soon for updates!
Howard is Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan Kettering and a board-certified medical oncologist with special expertise in treating men with advanced prostate cancer.
Chris Blaxland has over 30 years of experience in small and large companies, in general management, product development, and marketing and aspects of the industry. His 20 years at GlaxoSmithKline (SmithKline Beecham and SK&F) included worldwide responsibility as Vice President of Strategic Product Development. Chris is a Principal of Hunter Partners, LLC, a consultancy that provides advice and interim management for early to mid-stage pharmaceutical, biotech and medical device companies.
Chief Executive Officer (Permanent Position to Replace Acting CEO) – Open Position ProstaGene is currently seeking a CEO to direct its strategic and tactical planning, to oversee and execute its subcontracted development programs and prostate testing technology, and to provide oversight with the Executive Chairman to its Senior Licensing Executive (see below).
Dan W. Matthias is a member of the Board of Trustees of the Wistar Institute and its Intellectual Property and Scientific Advisory Committees as well as a member of the Board of Trustees of Thomas Jefferson University and its Biotechnology Committee. He is the retired Chairman, CEO, and Co-Founder of Mothers Work, Inc., a $500 million public company that manufactures and sells maternity apparel through over a thousand stores in the U.S. and Canada. (Since his retirement, the company’s name has been changed to Destination Maternity and it continues to be listed on NASDAQ, as DEST.)
Prior to Mothers Work, Mr. Matthias was involved in the computer and electronics industry. He was the President and Founder of a division of Exxon Corporation which designed and produced the first desk top word processor, and a Director of Zilog, an early micro-computer chip startup, for which he led initial funding. He is a graduate of Georgia Institute of Technology (BEE, MSEE) and Harvard Business School (MBA).
Rebecca Matthias has advised and assisted Dr. Pestell with strategic business matters and with financial planning and control, accounting, and reporting, and will continue to do so at no cost to the company. She and Mr. Matthias (see above) provided the initial financial investments needed for worldwide patent filings and patent prosecution to protect the company’s technologies.
Rebecca Matthias is the former President, Founder and Chief Creative Officer of Destination Maternity Corporation (Nasdaq: DEST), a $500 million public company that manufactures and sells maternity apparel at over 3000 locations in the U.S., Canada and other countries. She is a graduate of M.I.T (ME, Civil), Columbia University (M Arch), and The University of Pennsylvania (BA). She serves on the Board of CSS Industries, a New York Stock Exchange company, and chairs its Nominating and Governance Committee; and is a director of Penn Series Funds, a division of Penn Mutual Corp, its Lead Director and Chair of the Audit Committee. Formerly, she sat on the Board of The Russell Corporation, a New York Stock Exchange company, (until its sale to Berkshire Hathaway, Inc. in 2006). Other emeritus Board positions include: Drexel University, and The University of Pennsylvania, School of Arts and Sciences. Ms. Matthias is the author of the book ‘Mothers Work’ (Doubleday), about her experiences starting up a business.
Since retiring from Destination Maternity, Ms. Matthias has become involved with a number of entrepreneurial ventures. She is a founding investor/consultant at ProstaGene. She also sits on the board of Honey Grow, a rapidly expanding chain of farm-to-table casual restaurants; and Lacoda, a software servicing company for the nascent peer-to-peer lending and asset based lending industries.
- Professor of Finance, Stern School of Business, New York University.
- President and Chief Operating Officer of PREIT since 2004-2012.
- Executive Vice President and Chief Financial Officer of PREIT from 1997 to 2004.
Mr. Glickman began his professional career as an investment banker in New York City before joining The Rubin Organization as its chief financial officer. The Rubin Organization was acquired by PREIT in 1997. He initially served PREIT as its Chief Financial Officer before becoming its President and Chief Operating Officer in 2004 and a member of its Office of the Chair.
Mr. Glickman brings to the Board of Trustees, among other skills, a deep understanding of public and private capital markets, the day-to-day operations and personnel of PREIT and economic conditions and developments that directly or indirectly affect the business and strategic direction of PREIT.
Distinguished Professor and Director, Center for Integrated Bioinformatics, School of Biomedical Engineering, Science & Health Systems
Dr. Tozeren brings decade of experience in analysis of high density data sets for interpretation of molecular signatures for medical applications.